Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OnabotulinumtoxinA X for Moderate to Severe Glabellar Lines
NCT05100199Phase 2Completed
- Sponsor
- Allergan
- Start
- Oct 2021
- Primary completion
- Dec 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of onabotulinumtoxinA in glabellar lines, sponsored by Allergan. Started Oct 2021; status: completed.
02
Drugs
onabotulinumtoxinA
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT05100199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05100199.